New drug combo for T-cell leukemia or lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of drugs (LP-118, ponatinib, vincristine, and dexamethasone) for people with T-cell leukemia or lymphoma that has returned or not responded to prior treatments. The goal is to see if this combination can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have T-cell acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma that has come back or not responded to treatment.
- You must be 18 years old or older.
- Your leukemia or lymphoma must be measurable in your blood, bone marrow, or as a visible tumor on a CT scan.
- Your kidneys and liver must be working well enough, based on blood tests.
- You cannot have active leukemia in your brain or spinal cord, or an active infection like hepatitis B, C, or HIV (unless HIV is well-controlled).
- You must be willing to use effective birth control during the study and for several months after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs (EPOCH) plus a targeted therapy (ponatinib) for patients with a specific type of acute lymphoblastic leukemia (Ph+ ALL). Some participants also get rituximab if their leukemia cells have a certain marker (CD20). The goal is to see how well this treatment works as a first therapy.
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
This trial tests a new combination of drugs for adults newly diagnosed with a specific type of acute lymphoblastic leukemia (ALL) that has the Philadelphia chromosome. The goal is to see if this combination is safe and effective in treating the disease.
This trial tests two drugs, azacitidine and abatacept, given together for T-cell lymphoma that has come back or not improved after earlier treatment. The goal is to see if this combination can control the cancer better, potentially offering a new option for patients.
This trial tests a new combination of three drugs (a third-generation TKI, azacitidine, and a Bcl-2 inhibitor) for people with chronic myeloid leukemia that has progressed to a more advanced phase (myeloid blast phase). The goal is to see if this combination is safe and effective.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.